CIK 0000906709 · Non-accelerated filer<br>Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 943134940
- Phone
- 4154825300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $43,476
- in 2 filings
Net −$43,476. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-23 | WHITFIELD ROY A Director | Grant or award | +2,000 | 16,417 | ||
| 2026-09-23 | WHITFIELD ROY A Director | Grant or award · Stock Option | +4,000 | 4,000 | ||
| 2026-09-23 | GREER R SCOTT Director | Grant or award | +2,000 | 22,239 | ||
| 2026-09-23 | GREER R SCOTT Director | Grant or award · Stock Option | +4,000 | 4,000 | ||
| 2026-09-23 | CHESS ROBERT Director | Grant or award | +2,000 | 19,019 | ||
| 2026-09-23 | CHESS ROBERT Director | Grant or award · Stock Option | +4,000 | 4,000 | ||
| 2026-09-23 | Brainard Diana Director | Grant or award | +2,000 | 3,904 | ||
| 2026-09-23 | Brainard Diana Director | Grant or award · Stock Option | +4,000 | 4,000 | ||
| 2026-09-23 | Ajer Jeffrey Robert Director | Grant or award | +2,000 | 4,277 | ||
| 2026-09-23 | Ajer Jeffrey Robert Director | Grant or award · Stock Option | +4,000 | 4,000 | ||
| 2026-08-18 | Zalevsky Jonathan Chief R&D Officer | Sale | −186 | $71.98 | $13K | 9,570 |
| 2026-08-18 | ROBIN HOWARD W President & CEO | Sale | −418 | $71.98 | $30K | 54,627 |
| 2026-07-24 | Zalevsky Jonathan Chief R&D Officer | Grant or award · Stock Option | +16,500 | 16,500 | ||
| 2026-07-24 | ROBIN HOWARD W President & CEO | Grant or award · Stock Option | +57,200 | 57,200 | ||
| 2026-06-30 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −5,681 | $70.00 | $398K | 9,756 |
| 2026-06-17 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −5,500 | $60.81 | $334K | 59,545 |
| 2026-06-17 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −4,500 | $61.65 | $277K | 55,045 |
| 2026-06-16 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −5,303 | $59.97 | $318K | 69,742 |
| 2026-06-16 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −4,697 | $60.71 | $285K | 65,045 |
| 2026-06-15 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −5,538 | $60.71 | $336K | 15,437 |
Page 1 of 18 · 355 trades